Skip to content
Independent analysis of NHS open data
PharmaInsight

Efanesoctocog alfa 2,000unit powder and solvent for solution for injection vials

Secondary Care Medicines Data (SCMD) · indicative cost
Data updated April 2026

NHS hospitals in England used £19,161,600 of indicative cost of Efanesoctocog alfa 2,000unit powder and solvent for solution for injection vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 0.0% on the previous 12 months.

£19,161,600 0%

Indicative cost · 12 months

3,992units

Quantity (VMP units) · 12 months

0.1%

Share of hospital medicines spend

Figure 1. Efanesoctocog alfa 2,000unit powder and solvent for solution for injection vials: NHS hospital indicative cost by month (£ millions)

£0m £1.7m £3.5m Mar 2025 Jul 2025 Sep 2025 Nov 2025 Jan 2026 Apr 2026 £3.1m Mar 2025: £0.1m Jun 2025: £0.1m Jul 2025: £0.5m Aug 2025: £0.6m Sep 2025: £1.0m Oct 2025: £1.3m Nov 2025: £1.9m Dec 2025: £2.5m Jan 2026: £1.9m Feb 2026: £2.7m Mar 2026: £3.5m Apr 2026: £3.1m

Source: NHSBSA Secondary Care Medicines Data, to April 2026

Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.

NHS trusts using Efanesoctocog alfa 2,000unit powder and solvent for solution for injection vials most

By indicative cost over the 12 months to April 2026.

NHS trusts using Efanesoctocog alfa 2,000unit powder and solvent for solution for injection vials most, by indicative cost
NHS trustIndicative cost (12 months)
Royal Free London Nhs Foundation Trust £9,427,200
Barts Health Nhs Trust £3,105,600
East Kent Hospitals University Nhs Ft £2,289,600
Nottingham University Hospitals Trust £1,137,600
Guy's & St Thomas' Nhs Foundation Trust £960,000
Sheffield Teaching Hospitals Nhs Trust £523,200
Univ Hpl B/Ham Nhs Foundation Trust £374,400
Sheffield Children's Nhs Ft £297,600
University Hpls Of Leicester Nhs Trust £268,800
Derby Teaching Hospitals Nhs Found Trust £220,800

The primary-care picture

No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.